安罗替尼治疗晚期非小细胞肺癌的疗效及安全性评价

陈丽娟; 叶永青; 李殿明

doi:10.13898/j.cnki.issn.1000-2200.2021.05.016

安罗替尼治疗晚期非小细胞肺癌的疗效及安全性评价

Evaluation of the efficacy and safety of amlotinib in the treatment of advanced non-small cell lung cancer

摘要

摘要:
目的探讨安罗替尼治疗晚期非小细胞肺癌（NSCLC）的疗效及安全性。
方法回顾性分析应用安罗替尼治疗的50例晚期NSCLC病人资料，其中有45例病人接受安罗替尼三线治疗，5例病人接受四线治疗。分析评估安罗替尼的疗效及安全性。
结果最终47例病人纳入研究，无完全缓解的病人，部分缓解2例（4.26%），病情稳定24例（51.06%），病情进展21例（44.68%）。客观缓解率及疾病控制率分别是4.26%和55.32%，中位总生存时间（mOS）及中位无进展生存时间（mPFS）分别是8.6个月（95%CI 5.853~11.347）和4.8个月（95%CI 2.904~6.696）；≥60岁病人mOS及mPFS分别为8.6个月（95%CI 5.853~11.347）、5.8个月（95%CI 4.283~7.317）。使用安罗替尼发生的不良反应基本可耐受，发生率较高的不良反应为厌食、咯血、肝功能异常、手足综合征、高血压。
结论安罗替尼作为晚期NSCLC病人三线及以上治疗是可行的方案。

Abstract:
ObjectiveTo explore the efficacy and safety of anlotinib in the treatment of advanced non-small cell lung cancer(NSCLC).
MethodsThe clinical data of 50 advanced NSCLC patients treated with anlotinib were retrospectively analyzed.Forty-five patients were treated with anrotinib of third-line drug, and 5 patients were treated with fourth-line drug.The efficacy and safety of anlotinib were analyzed.
ResultsForty-seven patients were investigated, and the complete response in 0 case, partial response in 2 cases(4.26%), stable disease in 24 cases(51.06%) and disease progression in 21 cases(44.68%) were found.The objective response rate(ORR) and disease control rate(DCR) were 4.3% and 55.3%, respectively.The median overall survival(mOS) and median progression-free survival(mPFS) were 8.6 months(95%CI 5.853-11.347) and 4.8 months(95%CI 2.904-6.696), respectively.The mOS and mPFS in elderly patients(≥ 60 years old) were 8.6 months(95%CI 5.853-11.347) and 5.8 months(95%CI 4.283-7.317), respectively.The adverse reactions caused by the use of amlotinib were basically tolerable, and the high incidence rate of adverse reactions included anorexia, hemoptysis, abnormal liver function, hand-foot syndrome and hypertension.
ConclusionsAnlotinib is a viable option for third-line and above in patients with advanced NSCLC

HTML全文

参考文献(19)

施引文献

资源附件(0)